# Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

> **NCT05241392** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Tiantan Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** B7-H3-targeting CAR-T cells

## Key facts

- **NCT ID:** NCT05241392
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-27
- **Primary completion:** 2024-11-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05241392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05241392, "Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05241392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*